



*TFW*

Atty. Dkt. No. 029318-0107

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Bosch et al.  
Title: STERILE FILTERED NANOPARTICULATE FORMULATIONS OF BUDESONIDE  
AND BECLOMETHASONE HAVING TYLOXAPOL AS A SURFACE STABILIZER  
Appl. No.: 10/035,324  
Filing Date: 01/04/2002  
Examiner: Mina Haghighatian  
Art Unit: 1616

**STATEMENT OF SUBSTANCE OF INTERVIEW**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance to 37 C.F.R. § 1.133, submitted herewith is a record of the substance of the interview on February 21, 2006, between Examiner Mina Haghighatian, regarding the above-captioned application. This statement is being submitted within one (1) month of the mailing date of March 14, 2006, of the Interview Summary and is therefore a timely response.

**REMARKS**


Applicant wishes to thank Examiner Haghghatian and her supervisor, Examiner Padmanabhan for the courtesies extended by them during a February 21<sup>st</sup> telephonic interview.

The claims as amended in Applicant's response filed on February 28, 2006 reflect the substance of the claim amendments discussed during the interview. Applicant and Applicant's representatives set forth reasons as to why sterile filtered nanoparticulate compositions as presently claimed are distinct from nanoparticulate compositions that are not sterile filtered. Applicant and Applicant's representatives also asserted that it was surprisingly discovered that nanoparticulate beclomethasone or budesonide particles having tyloxapol as a surface modifier can be prepared at a very small particle size allowing for sterile filtering.

Respectfully submitted,

Date March 28, 2006

FOLEY & LARDNER LLP  
Customer Number: 31049  
Telephone: (202) 672-5538  
Facsimile: (202) 672-5399

By 

Michele M. Simkin  
Attorney for Applicant  
Registration No. 34,717